Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Organogenesis Holdings Inc.NASDAQ: ORGO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $3.64M rose 8.0% year over year, behind the +17.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 15.9% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.
Context
- Stock-based compensation amounted to 2.4% of revenue in FY2025, up 0.2 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +8.0% toward the trailing-twelve-month pace of +17.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 13.3M USD
- Year-over-year change
- +25.7%
- 4-year CAGR
- +36.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.3M | +25.7% |
| FY2024 | 2024-12-31 | 10.58M | +17.6% |
| FY2023 | 2023-12-31 | 9M | +37.3% |
| FY2022 | 2022-12-31 | 6.55M | +69.6% |
| FY2021 | 2021-12-31 | 3.86M | — |
Stock-Based Compensation vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.6% is the 4th highest of 11, against a peer median of -4.1%.
- Stock-based compensation amounts to 2.6% of revenue for ORGO, versus a peer median of 3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.89M USD | -13.9% | +24.1% | 6.6% | |
| LTM Mar 2026 | $16.6M USD | +22.1% | -28.9% | 2.5% | |
| LTM Mar 2026 | $13.57M USD | +17.6% | +26.6% | 2.6% | |
| LTM Mar 2026 | CA$13.13M CAD | -20.8% | +12.9% | 1.4% | |
| LTM Feb 2026 | $11.69M USD | +16.5% | -3.0% | 3.7% | |
| LTM Mar 2026 | $10.93M USD | +20.5% | +16.2% | — | |
| LTM Apr 2026 | $10.9M USD | -28.8% | +2.3% | 1.3% | |
| LTM Mar 2026 | $9.91M USD | -11.7% | -13.4% | 2.4% | |
| LTM Mar 2026 | $4.07M USD | +87.9% | +43.4% | — | |
| LTM Mar 2026 | $3.53M USD | +3.6% | +27.4% | 3.8% | |
| LTM Mar 2026 | $2.68M USD | -107.0% | +13.8% | 4.2% | |
| Peer median (excluding ORGO) | — | -4.1% | +13.3% | 3.1% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 94.9M | 15.53M | 4.95M | 861K | 37.03M |
| Depreciation & Amortization | 16.68M | 10.73M | 23.45M | 17.03M | 26.94M |
| Deferred Income Tax | (31.98M) | 1.98M | 2.01M | (10.72M) | 9.5M |
| Stock-Based Compensation | 3.86M | 6.55M | 9M | 10.58M | 13.3M |
| Change in Working Capital | (39.29M) | (34.08M) | (18.07M) | (48.89M) | (132.38M) |
| Accounts Receivables | (30.23M) | (8.77M) | 5.54M | (31.8M) | (115.8M) |
| Inventory | (9.3M) | (9.41M) | 6.58M | (6.2M) | (17.92M) |
| Accounts Payables | 3.85M | 3.26M | (108K) | (2.37M) | (528K) |
| Other Working Capital | (3.6M) | (19.16M) | (30.08M) | (8.51M) | 1.87M |
| Other Non-Cash Items | 17.8M | 24.15M | 9.59M | 45.35M | 35.3M |
| Operating Cash Flow | 61.98M | 24.86M | 30.92M | 14.21M | (10.31M) |
| Capital Expenditures | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (31.22M) | (33.9M) | (24.36M) | (10.03M) | (14.15M) |
| Debt Repayment | (2.01M) | (3.01M) | (5.17M) | (67.64M) | (1.17M) |
| Common Stock Issued | 2.2M | 0 | 0 | 0 | 157K |
| Common Stock Repurchased | 0 | 0 | 0 | (25.48M) | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.8M) | 0 |
| Other Financing Activities | (1.22M) | 814K | (332K) | 1.87M | (16.35M) |
| Financing Cash Flow | (1.04M) | (2.2M) | (5.51M) | 27.64M | (17.36M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 29.72M | (11.24M) | 1.05M | 31.81M | (41.82M) |
| Free Cash Flow | 30.76M | (9.04M) | 6.55M | 4.18M | (24.46M) |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.